Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

Abstract

BACKGROUND/AIMS Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are common causes of nephrotic syndrome (NS) in adults. However, induction of remission and sustained control of proteinuria is often difficult. Recently, B cell-directed therapy using the anti-CD20 antibody rituximab has been suggested as induction regimen in… (More)
DOI: 10.1159/000335142

Topics

Cite this paper

@article{Kisner2012RituximabTF, title={Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.}, author={Tuelay Kisner and Volker Burst and Sven Teschner and Thomas Benzing and Christine E. Kurschat}, journal={Nephron. Clinical practice}, year={2012}, volume={120 2}, pages={c79-85} }